1. Home
  2. PLXS vs BLTE Comparison

PLXS vs BLTE Comparison

Compare PLXS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plexus Corp.

PLXS

Plexus Corp.

HOLD

Current Price

$274.70

Market Cap

6.7B

Sector

Technology

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$158.50

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLXS
BLTE
Founded
1979
2018
Country
United States
United States
Employees
20000
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
6.0B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
PLXS
BLTE
Price
$274.70
$158.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$206.50
$198.00
AVG Volume (30 Days)
303.1K
143.1K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
56.11
N/A
EPS
3.32
N/A
Revenue
N/A
N/A
Revenue This Year
$14.31
N/A
Revenue Next Year
$8.29
$492.11
P/E Ratio
$83.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$126.86
$60.00
52 Week High
$307.06
$200.00

Technical Indicators

Market Signals
Indicator
PLXS
BLTE
Relative Strength Index (RSI) 58.19 54.65
Support Level $269.81 $145.11
Resistance Level $300.15 $160.72
Average True Range (ATR) 12.06 5.85
MACD 3.04 0.04
Stochastic Oscillator 93.94 64.74

Price Performance

Historical Comparison
PLXS
BLTE

About PLXS Plexus Corp.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: